$ISEE News
Last published 3y ago
- 3y agoISEEApproval of Izervay, Nda #217225 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 08/04/2023; Drug Name: Izervay, Nda #217225; Active Ingredients: AVACINCAPTAD PEGOL SODIUM; Company: Iveric Bio; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 217225
- 3y agoALPMYISEETYO:4503Astellas Completes Acquisition of Iveric BioPR NewswireTOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the acquisition of
- 3y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on July 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees.
- 3y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to three newly-hired, non-executive employees.
- 3y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on May 19, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 63 newly-hired, non-executive employees.
- 3y agoALPMYISEETYO:4503Astellas Enters into Definitive Agreement to Acquire Iveric BioPR Newswire-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas'
- 3y agoISEEAstellas Enters Into Definitive Agreement to Acquire Iveric BioBusiness Wire-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023- -Acquisition advances Astellas'
- 3y agoISEEIveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual MeetingBusiness Wire- Post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol (ACP) was correlated with reduced geographic atrophy (GA) growth - -
- 3y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on April 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.
- 3y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on March 1, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.
- 3y agoISEEIveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial ResultsBusiness Wire- FDA Accepts Filing of New Drug Application and Grants Priority Review for Avacincaptad Pegol (ACP) for the Treatment of Geographic Atrophy; PDUFA Goal Date is August 19, 2023 - - Post-hoc Time-to-Event Analysis of
- 3y agoISEEIveric Bio Announces Vision Loss Reduction Data in Geographic Atrophy from Avacincaptad Pegol GATHER TrialsBusiness Wire- Post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months - - Analysis to be presented at the ARVO Annual Meeting from April 23-27, 2023 - IVERIC
- 3y agoISEEIVERIC Bio (ISEE) Q4 2022 Earnings Call TranscriptEarnings Call TranscriptsISEE earnings call for the period ending December 31, 2022.
- 3y agoISEEIveric Bio to Present at the Cowen 43rd Annual Health Care ConferenceBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference
- 3y agoISEEIveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on Wednesday, March 1, 2023Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Wednesday, March 1, 2023. Following the announcement, the Iveric Bio management
- 3y agoISEEIveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic AtrophyBusiness Wire- PDUFA goal date is August 19, 2023 - IVERIC bio, Inc. (NASDAQ:ISEE) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company's New Drug Application
- 3y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on February 1, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to 16 newly-hired, non-executive employees.
- 3y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on January 3, 2023, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to twelve newly-hired, non-executive
- 3y agoISEEIveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of DirectorsBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to
- 3y agoISEEIveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic AtrophyBusiness Wire- Commercial launch preparations continue to accelerate - IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug
- 3y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on December 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive
- 3y agoISEEIveric Bio Announces Pricing of $300 Million Public Offering of Common StockBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less
- 3y agoISEEIveric Bio Announces Proposed Offering of Common StockBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) (the "Company"), today announced that it is commencing an underwritten public offering of $250.0 million of shares of its common stock. In addition, the Company intends to grant the
- 3y agoISEEIveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic AtrophyBusiness Wire- Designation based on 12-month primary endpoint data from GATHER pivotal trials - - Avacincaptad pegol (ACP) is the only investigational product for treatment of GA to achieve two positive phase 3 pivotal trials with
- 4y agoISEEIveric Bio to Present at Upcoming Investor ConferencesBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that Iveric Bio management will participate in fireside chats at the following investor conferences in November: Credit Suisse 31st Annual Healthcare Conference
- 4y agoISEEIveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic AtrophyBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the first part of its New Drug Application (NDA) for rolling review of avacincaptad pegol (ACP, also
- 4y agoISEEIveric Bio Reports Third Quarter 2022 Operational Highlights and Financial ResultsBusiness Wire- Reported Positive GATHER2 Results for Avacincaptad Pegol in Geographic Atrophy - - Planned NDA Submission Moved Up to End of This Year - - Received Favorable Feedback from FDA on Intermediate AMD Development Plan
- 4y agoISEEIVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call TranscriptEarnings Call TranscriptsISEE earnings call for the period ending September 30, 2022.
- 4y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on November 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive
- 4y agoISEEIveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022. Following the announcement, the Iveric Bio management team will
- 4y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on October 3, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees. These inducement grants were appro
- 4y agoISEEIveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual MeetingBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that top-line efficacy and safety results from GATHER2, the Company's second Phase 3 clinical trial of avacincaptad pegol (ACP, also known as Zimura®), an investigational complement C5 inhibitor bein
- 4y agoISEEOpen-Label Extension for Subjects Who Previously Completed Phase 3 Study ISEE2008. - NCT05536297ClinicalTrials.govAdverse Events
- 4y agoISEEIveric Bio to Present at Upcoming Investor ConferencesBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in fireside chats at the following two investor conferences in September: Wells Fargo 2022 Heal
- 4y agoISEEIveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic AtrophyBusiness Wire- Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area - - Statistically Significant Result w
- 4y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on September 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees. These inducement grants were app
- 4y agoISEEIveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual ConferenceBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a panel discussion titled, "Differentiation in Emerging Treatments for GA dAMD -- Perspectives From ISEE," at the H.C. Wainwright 2nd Annual Ophtha
- 4y agoISEEIveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022Business WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Keith Westby, Chief Operating Officer, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022
- 4y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on August 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees. These inducement grants were approv
- 4y agoISEEIveric Bio Reports Second Quarter 2022 Operational Highlights and Financial ResultsBusiness Wire- Zimura® GATHER2 Topline Data Expected in September of this Year- - GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92.5% – - Agreement for up to $250 Million in Non-dilutive Debt Financing
- 4y agoHTGCISEEIveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley BankBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that it has entered into a term loan debt financing facility with Hercules Capital, Inc. (NYSE:HTGC) and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-
- 4y agoISEEIVERIC bio, Inc. (ISEE) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsISEE earnings call for the period ending June 30, 2022.
- 4y agoISEEIveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today announced that it will report its second quarter 2022 financial and operating results on Tuesday, July 26, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast
- 4y agoISEEIveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists MeetingBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that in a post-hoc analysis from the GATHER1 clinical trial, Zimura showed a reduction of geographic atrophy lesion growth, compared to sham, across all distances from the foveal center point. The analysis
- 4y agoISEEDelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®PR NewswirePARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (NASDAQ:ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of
- 4y agoISEEIveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®Business WireIVERIC bio, Inc. (NASDAQ:ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech's silica-based sus
- 4y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on July 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee. These inducement grants were approved
- 4y agoISEEIveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic AtrophyBusiness WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today a post-hoc analysis from the Zimura® (avacincaptad pegol) GATHER1 clinical trial which explored enhanced Optical Coherence Tomography (OCT) image analysis to examine the effect of Zimura on change in Ellip
- 4y agoISEEIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIVERIC bio, Inc. (NASDAQ:ISEE) today reported that on June 1, 2022, the Company granted equity-based awards pursuant to the Company's 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees. These inducement grants were approv
- 4y agoISEEIveric Bio to Present at the UBS Global Healthcare Conference 2022Business WireIVERIC bio, Inc. (NASDAQ:ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 on Monday, May 23, 2022, at 10:45 a.m. Eastern Time. Investors and the general publ